18.51
Arcturus Therapeutics Holdings Inc stock is traded at $18.51, with a volume of 505.27K.
It is up +5.89% in the last 24 hours and up +27.39% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
See More
Previous Close:
$17.48
Open:
$17.53
24h Volume:
505.27K
Relative Volume:
0.95
Market Cap:
$502.63M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-15.96
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
-4.98%
1M Performance:
+27.39%
6M Performance:
+4.16%
1Y Performance:
-13.79%
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ARCT
Arcturus Therapeutics Holdings Inc
|
18.51 | 486.34M | 157.75M | -29.73M | -21.00M | -1.16 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-28-25 | Initiated | Scotiabank | Sector Outperform |
Jan-28-25 | Initiated | BTIG Research | Buy |
Aug-12-24 | Initiated | Leerink Partners | Outperform |
Dec-13-23 | Initiated | Canaccord Genuity | Buy |
Jul-24-23 | Initiated | William Blair | Outperform |
May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
Nov-14-22 | Resumed | Wells Fargo | Overweight |
Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
Jun-25-21 | Resumed | Goldman | Neutral |
Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
Jun-04-21 | Resumed | Robert W. Baird | Neutral |
Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
Jan-07-21 | Initiated | Wells Fargo | Overweight |
Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
Dec-08-20 | Reiterated | B. Riley Securities | Buy |
Dec-07-20 | Reiterated | B. Riley Securities | Buy |
Oct-26-20 | Initiated | Barclays | Overweight |
Oct-06-20 | Initiated | Citigroup | Buy |
Aug-26-20 | Initiated | Piper Sandler | Overweight |
Jul-30-20 | Resumed | ROTH Capital | Buy |
Jul-16-20 | Initiated | Raymond James | Outperform |
Jul-13-20 | Initiated | B. Riley FBR | Buy |
Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
Feb-11-20 | Initiated | Robert W. Baird | Outperform |
Feb-07-20 | Initiated | Guggenheim | Buy |
Feb-06-20 | Initiated | Guggenheim | Buy |
Apr-05-19 | Initiated | H.C. Wainwright | Buy |
Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Is Arcturus Therapeutics Holdings Inc. the Top Chart Pick This Week2025 Key Lessons & AI Driven Price Forecasts - kangso.co.kr
Arcturus Therapeutics Holdings Inc. Added to High Probability Setup ListWeekly Stock Summary & Accurate Technical Buy Alerts - beatles.ru
Arcturus Therapeutics Stock Rises After Promising Mid-Stage Data for OTC Deficiency Treatment - MSN
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript - MSN
Is Now a Good Time to Reenter Arcturus Therapeutics Holdings Inc.July 2025 Breakouts & Safe Capital Allocation Plans - beatles.ru
Arcturus Therapeutics (ARCT) Surges 29% on Intraday Frenzy: What’s Fueling the Biotech Breakout? - AInvest
Intapp Posts Better-Than-Expected Earnings, Joins… - inkl
Arcturus Therapeutics (NASDAQ:ARCT) Upgraded at Wall Street Zen - MarketBeat
Arcturus Therapeutics Receives Bullish Rating Amid Promising Cystic Fibrosis and COVID-19 Vaccine Progress - AInvest
Citi Raises Arcturus Therapeutics Price Target to $49, Keeps Buy Rating - AInvest
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating - 富途牛牛
Mercury Systems Surges 24.6% After Reporting Better-Than-Expected Q4 Earnings, Green Dot, Arcturus Therapeutics, and Other Stocks Rise Amid US Market Gains - AInvest
Mercury Systems Posts Better-Than-Expected Earnings,… - inkl
Arcturus Therapeutics shares rise 29.68% intraday after positive interim Phase 2 data for ARCT-810. - AInvest
Real Messenger Corporation shares rise 28.05% intraday after Arcturus Therapeutics announced positive Phase 2 data for ARCT-810. - AInvest
Arcturus Therapeutics: Wells Fargo Maintains Overweight, PT Down to $42 from $45 - AInvest
Wells Fargo lowers Arcturus Therapeutics stock price target to $42 on model updates - Investing.com Canada
Arcturus Therapeutics shares rise 6.23% premarket after positive interim Phase 2 data for ARCT-810. - AInvest
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress - BioSpace
Arcturus Therapeutics Reports Q2 2025 Earnings and Pipeline Progress - TipRanks
Arcturus Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates - Investing.com Nigeria
Arcturus Therapeutics Advances CF and OTC Programs, Plans Regulatory Meetings in 2026 - AInvest
Transcript : Arcturus Therapeutics Holdings Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Arcturus Tightens Its Belt As Analysts Stay Bullish - Finimize
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Arcturus Therapeutics: Q2 Earnings Snapshot - MarketScreener
Earnings call transcript: Arcturus Therapeutics Q2 2025 results miss expectations - Investing.com
Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arcturus Therapeutics Q2 net loss narrows - MarketScreener
Arcturus Therapeutics shares edge higher despite earnings miss in Q2 - Investing.com India
Arcturus Therapeutics shares edge higher despite earnings miss in Q2 By Investing.com - Investing.com Australia
Arcturus Therapeutics Q2 2025 Financial Update - TradingView
Short interest data insights for Arcturus Therapeutics Holdings Inc.Historical Market Behavior and Trend Summary - Newser
Risk vs reward if holding onto Arcturus Therapeutics Holdings Inc.Swing Trade Timing with Daily Forecast - Newser
Multi factor analysis applied to Arcturus Therapeutics Holdings Inc.High Yield Signals with Entry Timing - Newser
Arcturus Therapeutics Q2 2025 Earnings Preview: Analysts Expect EPS of -$0.87, Revenue of $18.71M. - AInvest
Arcturus Therapeutics Holdings Inc expected to post a loss of 89 cents a shareEarnings Preview - TradingView
What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q2 2025 Earnings - GuruFocus
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034 - GlobeNewswire Inc.
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Is Arcturus Therapeutics Holdings Inc. stock overvalued or undervaluedHigh-yield portfolio picks - Jammu Links News
What is the risk reward ratio of investing in Arcturus Therapeutics Holdings Inc. stockRapid return acceleration - Jammu Links News
How does Arcturus Therapeutics Holdings Inc. compare to its industry peersFree Risk Assessment Services - Jammu Links News
What are analysts’ price targets for Arcturus Therapeutics Holdings Inc. in the next 12 monthsBuild a winning investment portfolio - Jammu Links News
When is Arcturus Therapeutics Holdings Inc. stock expected to show significant growthDiscover breakthrough stocks before the crowd - Jammu Links News
Is Arcturus Therapeutics Holdings Inc. a growth stock or a value stockGet professional guidance for market timing - Jammu Links News
What catalysts could drive Arcturus Therapeutics Holdings Inc. stock higher in 2025Get alerts on high-potential stock breakouts - Jammu Links News
What drives Arcturus Therapeutics Holdings Inc. stock priceAchieve rapid financial growth with smart picks - Jammu Links News
What is Arcturus Therapeutics Holdings Inc. company’s growth strategyTremendous financial leverage - Jammu Links News
What are Arcturus Therapeutics Holdings Inc. company’s key revenue driversRapid return acceleration - Jammu Links News
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):